OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ERAS$10.6558

ERAS.O

Biotechnology & Medical ResearchVerified

ERAS.O has a strong liquidity position, with a current ratio of 10.04, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $73.8 million, which is a substantial portion of its total assets of $396.15 million. However, the company's liquidity is not supported by long-term debt, as it has no long-term debt on its balance sheet. Profitability metrics for ERAS.O are negative, with a return on equity (ROE) of -38.3% and a return on assets (ROA) of -31.44%. The company reported a net loss of $124.55 million and an operating loss of $140.91 million in the latest period. These figures indicate that the company is not currently generating returns for its shareholders and is operating at a loss. The company's revenue is not disclosed in the provided data, but its total equity of $325.17 million suggests that it is primarily funded through equity rather than debt. There is no information provided on specific segments or geographic regions contributing to the company's revenue, so it is unclear if the company has significant revenue concentration in any particular area. Looking ahead, the company's growth trajectory is uncertain. The latest financial data shows a continued loss, with operating cash flow of -$95.46 million and free cash flow of -$121.57 million. Analysts have provided a range of price targets, with a mean of $18.60 and a median of $20.00, suggesting some optimism about the company's future performance. Risk factors for ERAS.O include its negative profitability and the absence of long-term debt, which may limit its ability to finance growth through traditional means. The company's dilution risk is currently low, as there are no immediate filing-based liquidity or dilution flags. However, the company's reliance on equity financing could change if it needs to raise additional capital in the future. Recent events for ERAS.O include the latest financial reporting, which shows continued losses and negative cash flows. There is no indication of recent significant events such as major product launches, regulatory approvals, or strategic partnerships that could impact the company's financial performance.

30-day price · ERAS-5.73 (-31.5%)
Low$8.70High$24.28Close$12.47As of28 May, 00:00 UTC
Profile
CompanyERAS.O
TickerERAS.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. ERAS.O is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic tests and related services.

Classification. ERAS.O is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

ERAS.O has a strong liquidity position, with a current ratio of 10.04, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $73.8 million, which is a substantial portion of its total assets of $396.15 million. However, the company's liquidity is not supported by long-term debt, as it has no long-term debt on its balance sheet. Profitability metrics for ERAS.O are negative, with a return on equity (ROE) of -38.3% and a return on assets (ROA) of -31.44%. The company reported a net loss of $124.55 million and an operating loss of $140.91 million in the latest period. These figures indicate that the company is not currently generating returns for its shareholders and is operating at a loss. The company's revenue is not disclosed in the provided data, but its total equity of $325.17 million suggests that it is primarily funded through equity rather than debt. There is no information provided on specific segments or geographic regions contributing to the company's revenue, so it is unclear if the company has significant revenue concentration in any particular area. Looking ahead, the company's growth trajectory is uncertain. The latest financial data shows a continued loss, with operating cash flow of -$95.46 million and free cash flow of -$121.57 million. Analysts have provided a range of price targets, with a mean of $18.60 and a median of $20.00, suggesting some optimism about the company's future performance. Risk factors for ERAS.O include its negative profitability and the absence of long-term debt, which may limit its ability to finance growth through traditional means. The company's dilution risk is currently low, as there are no immediate filing-based liquidity or dilution flags. However, the company's reliance on equity financing could change if it needs to raise additional capital in the future. Recent events for ERAS.O include the latest financial reporting, which shows continued losses and negative cash flows. There is no indication of recent significant events such as major product launches, regulatory approvals, or strategic partnerships that could impact the company's financial performance.
Key takeaways
  • ERAS.O has a strong liquidity position with a current ratio of 10.04 and $73.8 million in cash and equivalents.
  • The company is currently unprofitable, with a return on equity of -38.3% and a return on assets of -31.44%.
  • ERAS.O has no long-term debt, indicating a conservative capital structure.
  • Analysts have provided a range of price targets, with a mean of $18.60 and a median of $20.00, suggesting some optimism about the company's future performance.
  • The company's growth trajectory is uncertain, with continued losses and negative cash flows.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is negative due to its current unprofitability and negative return on equity.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$140.9M
Net income-$124.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$95.5M
CapEx-$128.0k
Free cash flow-$121.6M
Total assets$396.2M
Total liabilities$71.0M
Total equity$325.2M
Cash & equivalents$73.8M
Long-term debt$0.00
Valuation
Market price$10.65
Market cap$3.31B
Enterprise value$3.24B
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B10.2
P/Tangible book10.2
Tangible book$325.2M
Net cash$73.8M
Current ratio10.0
Debt/Equity0.0
ROA-31.4%
ROE-38.3%
Cash conversion77.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricERASActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Mean price target18.60 USD
Median price target20.00 USD
High price target30.00 USD
Low price target5.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count6.00
Hold count1.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate-0.54 USD
Last actual EPS-0.44 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 20:37 UTC#2255da86
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 21:32 UTCJob: 7e15178e